FDA Approves Two Insulins
by DiabetesCare.net | Oct 6, 2015 | Medicine Cabinet
The Food and Drug Administration (FDA) has surprised healthcare professionals when it recently announced the approval of both insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg) 70/30. The FDA refused to approve Tresiba and Ryzodeg two years ago, citing concerns about the drugs’ adverse cardiovascular effects....
Does a Popular Type 2 Medicine Create a B12 Deficiency?
by DiabetesCare.net | Sep 15, 2015 | Medicine Cabinet
Metformin is recommended as initial therapy for type 2 diabetes and is used as monotherapy or in combination with other antidiabetic oral agents and insulin. It has been found to be an effective treatment for many patients, but it is also important to point some potential issues associated with taking it. For example, the drug’s side effects include...
Jardiance and Heart Disease
by DiabetesCare.net | Sep 2, 2015 | Medicine Cabinet
A new study states Jardiance (Empaglifluzin, Eli Lilly and Boehringer Ingelheim) reduces the risk of heart attacks, strokes and other cardiovascular damage. Jardiance is a sodium glucose transport (SGLT-2 inhibitor) inhibitor, and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. A three-year...
Statins: Risk Vs. Reward
by DiabetesCare.net | Aug 11, 2015 | Medicine Cabinet
Late last year, the American Diabetes Association (ADA) recommended the use of cholesterol-lowering medications (statins) in all patients with diabetes. ADA’s recommendation included moderate-intensity statins for people under age 40 with diabetes. Moderate-intensity statins are also recommended for those between ages 40 and 75 without risk factors for...
7 Tips on Safety and Adherence to Medication on Vacation
by DiabetesCare.net | Jul 24, 2015 | Medicine Cabinet
Poor adherence to medical treatment is widespread and well recognized. Poor adherence to medication therapy either because medication doses are forgotten or the patient experiences adverse effects and stops taking medication, may lead to poor health outcomes and increased healthcare costs. In the summer months, when many patients go on vacation, I find...
No Increased Heart Risks for DPP-4 inhibitors
by DiabetesCare.net | Jul 17, 2015 | Medicine Cabinet
Recently, there was a discussion surrounding the connection between dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk for cardiovascular disease (CVD) or hospitalization for heart failure (HF). Such concerns could affect providers’ prescribing habits of this class of drugs in general and could change the face of diabetes treatment if the CVD...
